Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial.

Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial. Ophthalmology. 2011 Jan; 118(1):111-8.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.